CD47 and malignant glioma: Malignant gliomas, especially grade IV glioblastoma (GBM), progress rapidly with a limited response to current therapies.[8] Analyses of The Cancer Genome Atlas (TCGA, https://www.cancer.gov/ccg/research/genome‐sequencing/tcga) dataset (n = 162) showed that CD47 and the macrophage marker CD68 are highly expressed in GBM tissues compared to CD274 (encoding PD‐L1) and CD3e (encoding a component of the TCR‐CD3 complex on the T‐lymphocyte cell membrane) (Figure 1A).